IM Cannabis (NASDAQ:IMCC) Vs. TLRY, CGC, USNA, CRON, ACB, SNDL, HEXO, CDXC, NAII, and MDWD
Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Tilray (TLRY), Canopy Growth (CGC), USANA Health Sciences (USNA), Cronos Group (CRON), Aurora Cannabis (ACB), Sundial Growers (SNDL), HEXO (HEXO), ChromaDex (CDXC), Natural Alternatives International (NAII), and MediWound (MDWD). These companies are all part of the "medicinals & botanicals" industry.These companies are all part of the "medicinals & botanicals" industry.
IM Cannabis vs.
Canopy Growth (NASDAQ:CGC) and IM Cannabis (NASDAQ:IMCC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation.
14.2% of Canopy Growth shares are owned by institutional investors. Comparatively, 13.7% of IM Cannabis shares are owned by institutional investors. 0.1% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
IM Cannabis has a net margin of -60.79% compared to Canopy Growth's net margin of -201.25%. IM Cannabis' return on equity of -20.69% beat Canopy Growth's return on equity.
Canopy Growth presently has a consensus price target of $24.19, suggesting a potential upside of 131.50%. IM Cannabis has a consensus price target of $8.42, suggesting a potential upside of 102.81%. Given Canopy Growth's higher possible upside, analysts clearly believe Canopy Growth is more favorable than IM Cannabis.
In the previous week, Canopy Growth had 4 more articles in the media than IM Cannabis. MarketBeat recorded 12 mentions for Canopy Growth and 8 mentions for IM Cannabis. Canopy Growth's average media sentiment score of 0.35 beat IM Cannabis' score of 0.29 indicating that Canopy Growth is being referred to more favorably in the media.
Canopy Growth received 8 more outperform votes than IM Cannabis when rated by MarketBeat users. However, 75.00% of users gave IM Cannabis an outperform vote while only 30.43% of users gave Canopy Growth an outperform vote.
IM Cannabis has lower revenue, but higher earnings than Canopy Growth. IM Cannabis is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Summary
IM Cannabis beats Canopy Growth on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IM Cannabis (NASDAQ:IMCC) vs. Its Competitors
IM Cannabis Competitors List
